{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:09:35Z","timestamp":1777860575794,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12325-024-02993-9","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:02:03Z","timestamp":1729051323000},"page":"4476-4497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Beh\u00e7et\u2019s Disease: A Post-Marketing Surveillance"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1204","authenticated-orcid":false,"given":"Toshifumi","family":"Hibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-7383","authenticated-orcid":false,"given":"Shunsei","family":"Hirohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1864-1098","authenticated-orcid":false,"given":"Hirotoshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-7046","authenticated-orcid":false,"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-0808","authenticated-orcid":false,"given":"Noriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-9792","authenticated-orcid":false,"given":"Naomi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-9261","authenticated-orcid":false,"given":"Yutaka","family":"Susuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2908-1452","authenticated-orcid":false,"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"2993_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med"},{"key":"2993_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","volume":"17","author":"A Greco","year":"2018","unstructured":"Greco A, De Virgilio A, Ralli M, et al. Beh\u00e7et\u2019s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17:567\u201375.","journal-title":"Autoimmun Rev"},{"key":"2993_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/diagnostics13010041","volume":"13","author":"F Alibaz-Oner","year":"2022","unstructured":"Alibaz-Oner F, Direskeneli H. Update on the diagnosis of Beh\u00e7et\u2019s disease. Diagnostics (Basel). 2022;13:41.","journal-title":"Diagnostics (Basel)"},{"key":"2993_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10238-004-0033-4","volume":"4","author":"M Suzuki Kurokawa","year":"2004","unstructured":"Suzuki Kurokawa M, Suzuki N. Behcet\u2019s disease. Clin Exp Med. 2004;4:10\u201320.","journal-title":"Clin Exp Med"},{"key":"2993_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","volume":"90","author":"H Ideguchi","year":"2011","unstructured":"Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Beh\u00e7et disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90:125\u201332.","journal-title":"Medicine (Baltimore)"},{"key":"2993_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12328-014-0488-0","volume":"7","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Beh\u00e7et\u2019s disease. Clin J Gastroenterol. 2014;7:205\u201312.","journal-title":"Clin J Gastroenterol"},{"key":"2993_CR7","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.2169\/internalmedicine.4705-20","volume":"59","author":"S Hirohata","year":"2020","unstructured":"Hirohata S, Kikuchi H, Sawada T, et al. Recommendations for the management of neuro-Beh\u00e7et\u2019s disease by the Japanese national research committee for Beh\u00e7et\u2019s disease. Intern Med. 2020;59:2359\u201367.","journal-title":"Intern Med"},{"key":"2993_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","volume":"19","author":"A Bettiol","year":"2023","unstructured":"Bettiol A, Alibaz-Oner F, Direskeneli H, et al. Vascular Beh\u00e7et syndrome: from pathogenesis to treatment. Nat Rev Rheumatol. 2023;19:111\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"2993_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","volume":"11","author":"MP de Chambrun","year":"2012","unstructured":"de Chambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Beh\u00e7et\u2019s disease. Autoimmun Rev. 2012;11:687\u201398.","journal-title":"Autoimmun Rev"},{"key":"2993_CR10","doi-asserted-by":"publisher","first-page":"8055","DOI":"10.1002\/jcp.27576","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A, Zamani MR, Shabga AG, et al. Beh\u00e7et\u2019s disease: an immunogenetic perspective. J Cell Physiol. 2019;234:8055\u201374.","journal-title":"J Cell Physiol"},{"key":"2993_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2249.2005.02695.x","volume":"139","author":"Y Imamura","year":"2005","unstructured":"Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet\u2019s disease. Clin Exp Immunol. 2005;139:371\u20138.","journal-title":"Clin Exp Immunol"},{"key":"2993_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/intimm\/dxt046","volume":"26","author":"\u015e Y\u00fcksel","year":"2014","unstructured":"Y\u00fcksel \u015e, Eren E, Hatemi G, et al. Novel NLRP3\/cryopyrin mutations and pro-inflammatory cytokine profiles in Beh\u00e7et\u2019s syndrome patients. Int Immunol. 2014;26:71\u201381.","journal-title":"Int Immunol"},{"key":"2993_CR13","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.2169\/internalmedicine.51.8583","volume":"51","author":"S Hirohata","year":"2012","unstructured":"Hirohata S, Kikuchi H. Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Beh\u00e7et\u2019s disease. Intern Med. 2012;51:3359\u201365.","journal-title":"Intern Med"},{"key":"2993_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5009\/gnl.2011.5.1.37","volume":"5","author":"K Kato","year":"2011","unstructured":"Kato K, Fukunaga K, Kamikozuru K, et al. Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid na\u00efve patients with Crohn\u2019s disease. Gut Liver. 2011;5:37\u201345.","journal-title":"Gut Liver"},{"key":"2993_CR15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-\u03b1 therapy in rheumatoid arthritis. J Immunol. 1999;163:1521\u20138.","journal-title":"J Immunol"},{"key":"2993_CR16","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol"},{"key":"2993_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase\u00a03 study. Medicine (Baltimore). 2016;95: e3863.","journal-title":"Medicine (Baltimore)"},{"key":"2993_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.5009\/gnl220278","volume":"17","author":"JH Cheon","year":"2023","unstructured":"Cheon JH, Kim HS, Han DS, et al. Efficacy and safety of infliximab in intestinal Beh\u00e7et\u2019s disease: a multicenter, phase\u00a03 study (BEGIN). Gut Liver. 2023;17:777\u201385.","journal-title":"Gut Liver"},{"key":"2993_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/ibd.20457","volume":"14","author":"M Naganuma","year":"2008","unstructured":"Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Beh\u00e7et\u2019s disease. Inflamm Bowel Dis. 2008;14:1259\u201364.","journal-title":"Inflamm Bowel Dis"},{"key":"2993_CR20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","volume":"52","author":"H Kinoshita","year":"2013","unstructured":"Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Beh\u00e7et\u2019s disease refractory to conventional medication. Intern Med. 2013;52:1855\u201362.","journal-title":"Intern Med"},{"key":"2993_CR21","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Beh\u00e7et\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"2993_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10620-016-4395-8","volume":"62","author":"J Zou","year":"2017","unstructured":"Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ. Long-term outcomes and predictors of sustained response in patients with intestinal Behcet\u2019s disease treated with infliximab. Dig Dis Sci. 2017;62:441\u20137.","journal-title":"Dig Dis Sci"},{"key":"2993_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","volume":"272","author":"H Kikuchi","year":"2008","unstructured":"Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Beh\u00e7et\u2019s syndrome. J Neurol Sci. 2008;272:99\u2013105.","journal-title":"J Neurol Sci"},{"key":"2993_CR24","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/1756-185X.14209","volume":"24","author":"D Yalcin Kehribar","year":"2021","unstructured":"Yalcin Kehribar D, Gunaydin S, Ozgen M. Infliximab therapy in parenchymal neuro-Beh\u00e7et\u2019s disease: a single-center experience. Int J Rheum Dis. 2021;24:1302\u20137.","journal-title":"Int J Rheum Dis"},{"key":"2993_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/acr.21557","volume":"64","author":"S Adler","year":"2012","unstructured":"Adler S, Baumgartner I, Villiger PM. Beh\u00e7et\u2019s disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res (Hoboken). 2012;64:607\u201311.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2993_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1177\/1708538120927701","volume":"28","author":"DY Kehribar","year":"2020","unstructured":"Kehribar DY, Ozgen M. Infliximab treatment in refractory vascular Behcet\u2019s disease: a single-center experience. Vascular. 2020;28:829\u201333.","journal-title":"Vascular"},{"key":"2993_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109682","volume":"253","author":"G Hatemi","year":"2023","unstructured":"Hatemi G, Tukek NB, Esatoglu SN, et al. Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome. Clin Immunol. 2023;253: 109682.","journal-title":"Clin Immunol"},{"key":"2993_CR28","unstructured":"Infliximab (Remicade) for IV infusion [Japanese package insert]. Horsham: Janssen Biotech, Inc.; 2022. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00048579.pdf [In Japanese]. Accessed June 5, 2024."},{"key":"2993_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3109\/s10165-010-0332-4","volume":"20","author":"T Matsui","year":"2010","unstructured":"Matsui T, Ishida T, Tono T, Yoshida T, Sato S, Hirohata S. An attack of acute neuro-Beh\u00e7et\u2019s disease during the course of chronic progressive neuro-Beh\u00e7et\u2019s disease: report of two cases. Mod Rheumatol. 2010;20:621\u20136.","journal-title":"Mod Rheumatol"},{"key":"2993_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"key":"2993_CR31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/jgh.15754","volume":"37","author":"M Zhang","year":"2022","unstructured":"Zhang M, Liu J, Liu T, et al. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet\u2019s disease, a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:608\u201319.","journal-title":"J Gastroenterol Hepatol"},{"key":"2993_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","volume":"22","author":"MJ Alomar","year":"2014","unstructured":"Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22:83\u201394.","journal-title":"Saudi Pharm J"},{"key":"2993_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/bmj.1.5643.536","volume":"1","author":"N Hurwitz","year":"1969","unstructured":"Hurwitz N. Predisposing factors in adverse reactions to drugs. Br Med J. 1969;1:536\u20139.","journal-title":"Br Med J"},{"key":"2993_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","volume":"21","author":"S Ohno","year":"2019","unstructured":"Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21:2.","journal-title":"Arthritis Res Ther"},{"key":"2993_CR35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","volume":"33","author":"S Ben-Horin","year":"2011","unstructured":"Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease. Aliment Pharmacol Ther. 2011;33:987\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"2993_CR36","first-page":"606","volume":"26","author":"MJ Casanova","year":"2020","unstructured":"Casanova MJ, Chaparro M, M\u00ednguez M, et al. Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the Eneida registry. Inflamm Bowel Dis. 2020;26:606\u201316.","journal-title":"Inflamm Bowel Dis"},{"key":"2993_CR37","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1097\/MIB.0000000000000475","volume":"21","author":"Y Suzuki","year":"2015","unstructured":"Suzuki Y, Matsui T, Ito H, et al. Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn\u2019s disease: a prospective clinical trial. Inflamm Bowel Dis. 2015;21:2114\u201322.","journal-title":"Inflamm Bowel Dis"},{"key":"2993_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","volume":"19","author":"T Takeuchi","year":"2009","unstructured":"Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T, RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19:478\u201387.","journal-title":"Mod Rheumatol"},{"key":"2993_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.reuma.2021.03.009","volume":"18","author":"L Serpa Pinto","year":"2022","unstructured":"Serpa Pinto L, Xavier Pires S, Silva B, Farinha F, Vasconcelos C, Ara\u00fajo CJ. Predictive factors of severe Beh\u00e7et\u2019s disease: a longitudinal, prospective cohort followed between 1981\u20132020. Reumatol Clin (Engl Ed). 2022;18:410\u20135.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2993_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fmed.2020.00517","volume":"2","author":"R Atreya","year":"2020","unstructured":"Atreya R, Neurath MF, Siegmund B. Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF? Front Med (Lausanne). 2020;2:517.","journal-title":"Front Med (Lausanne)"},{"key":"2993_CR41","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","volume":"12","author":"GM Leone","year":"2023","unstructured":"Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J Clin Med. 2023;12:1630.","journal-title":"J Clin Med"},{"key":"2993_CR42","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/apt.17170","volume":"56","author":"N Chanchlani","year":"2022","unstructured":"Chanchlani N, Lin S, Auth MK, et al. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study. Aliment Pharmacol Ther. 2022;56:1250\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"2993_CR43","doi-asserted-by":"publisher","first-page":"300060523116989","DOI":"10.1177\/03000605231169895","volume":"51","author":"RHA Mohammed","year":"2023","unstructured":"Mohammed RHA, Woldeamanuel YW. The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Beh\u00e7et\u2019s disease: a systematic review and meta-analysis. J Int Med Res. 2023;51:3000605231169895.","journal-title":"J Int Med Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02993-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T08:11:53Z","timestamp":1731139913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02993-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2993"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02993-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Mitsubishi Tanabe Pharma Corporation. T. Hibi., S.H., T. Hisamatsu, H.K., M. Takeno, and Y.I. have received consulting fees from Mitsubishi Tanabe Pharma Corporation. N.S., N.M., M. Tashiro, and Y.S. are employees of Mitsubishi Tanabe Pharma Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted according to the\u00a0Japanese Good Post-Marketing Surveillance Practices (GPSP, Pharmaceuticals and Medical Devices Agency, 2004). As per the GPSP, pre-registration as a clinical trial, informed consent, and study protocol approval by the institutional review board were not required for a PMS study. Therefore, no IRB was held for this study. The study protocol was approved through pre-consultation with the Pharmaceuticals and Medical Devices Agency, in accordance with the\u00a0GPSP. Data were made unidentifiable to individual patients, ensuring patient confidentiality and transparency regarding data privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}